DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
5.69
-0.03 (-0.52%)
May 21, 2026, 12:15 PM EDT - Market open
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
306.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Lineage Cell Therapeutics | 14.78M |
| Abeona Therapeutics | 14.54M |
| Opus Genetics | 11.98M |
| Surrozen | 7.49M |
| Silence Therapeutics | 839.00K |
DMAC News
- 1 day ago - DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial - TheFly
- 1 day ago - DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
- 8 days ago - DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - Business Wire
- 14 days ago - DiaMedica Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 14 days ago - DiaMedica Therapeutics Earnings release: Q1 2026 - Filings
- 14 days ago - DiaMedica Therapeutics Quarterly report: Q1 2026 - Filings
- 14 days ago - DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c) - TheFly
- 14 days ago - DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights - Business Wire